GlassScriptPhysician profile
Jason W Everman
NPI 1881866572
$3,197.90
in general payments reported to CMS, 2019-2025
36 companies · $868 in 2025
The $868 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $15.80 · 2021: $11.16 · 2022: $222 · 2023: $510 · 2024: $1,042 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $803.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $441.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $422.31 | 2019-2025 | |
| Pfizer INC. | $142.91 | 2022-2025 | |
| Amgen INC. | $142.40 | 2019-2025 | Evenity, Prolia, Otezla |
| Radius Health, INC. | $113.78 | 2019 | |
| Celgene Corporation | $113.11 | 2019 | |
| Glaxosmithkline, LLC. | $98.74 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $96.21 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $93.22 | 2022-2025 | Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $80.89 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $51.77 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $49.57 | 2024-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.25 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.50 | 2022-2023 | Xifaxan |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Everman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.